Your browser doesn't support javascript.
Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model.
Figl, Julia; Köhler, Heike; Wedlich, Nadine; Liebler-Tenorio, Elisabeth M; Grode, Leander; Parzmair, Gerald; Krishnamoorthy, Gopinath; Nieuwenhuizen, Natalie E; Kaufmann, Stefan H E; Menge, Christian.
  • Figl J; Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, 07743 Jena, Germany.
  • Köhler H; Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, 07743 Jena, Germany.
  • Wedlich N; Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, 07743 Jena, Germany.
  • Liebler-Tenorio EM; Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, 07743 Jena, Germany.
  • Grode L; Vakzine Projekt Management GmbH, 30625 Hannover, Germany.
  • Parzmair G; Vakzine Projekt Management GmbH, 30625 Hannover, Germany.
  • Krishnamoorthy G; Department of Immunology, Max Planck Institute for Infection Biology, 10117 Berlin, Germany.
  • Nieuwenhuizen NE; Department of Immunology, Max Planck Institute for Infection Biology, 10117 Berlin, Germany.
  • Kaufmann SHE; Department of Immunology, Max Planck Institute for Infection Biology, 10117 Berlin, Germany.
  • Menge C; Max Planck Institute for Multidisciplinary Sciences, 37077 Göttingen, Germany.
Int J Mol Sci ; 24(6)2023 Mar 14.
Article in English | MEDLINE | ID: covidwho-2259145
ABSTRACT
A more effective vaccine against tuberculosis than Bacille Calmette-Guérin (BCG) is urgently needed. BCG derived recombinant VPM1002 has been found to be more efficacious and safer than the parental strain in mice models. Newer candidates, such as VPM1002 Δpdx1 (PDX) and VPM1002 ΔnuoG (NUOG), were generated to further improve the safety profile or efficacy of the vaccine. Herein, we assessed the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, in juvenile goats. Vaccination did not affect the goats' health in regards to clinical/hematological features. However, all three tested vaccine candidates and BCG induced granulomas at the site of injection, with some of the nodules developing ulcerations approximately one month post-vaccination. Viable vaccine strains were cultured from the injection site wounds in a few NUOG- and PDX- vaccinated animals. At necropsy (127 days post-vaccination), BCG, VPM1002, and NUOG, but not PDX, still persisted at the injection granulomas. All strains, apart from NUOG, induced granuloma formation only in the lymph nodes draining the injection site. In one animal, the administered BCG strain was recovered from the mediastinal lymph nodes. Interferon gamma (IFN-γ) release assay showed that VPM1002 and NUOG induced a strong antigen-specific response comparable to that elicited by BCG, while the response to PDX was delayed. Flow cytometry analysis of IFN-γ production by CD4+, CD8+, and γδ T cells showed that CD4+ T cells of VPM1002- and NUOG-vaccinated goats produced more IFN-γ compared to BCG-vaccinated and mock-treated animals. In summary, the subcutaneous application of VPM1002 and NUOG induced anti-tuberculous immunity, while exhibiting a comparable safety profile to BCG in goats.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / BCG Vaccine Type of study: Prognostic study Topics: Vaccines Limits: Animals Language: English Year: 2023 Document Type: Article Affiliation country: Ijms24065509

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / BCG Vaccine Type of study: Prognostic study Topics: Vaccines Limits: Animals Language: English Year: 2023 Document Type: Article Affiliation country: Ijms24065509